Nuvalent (NUVL) Non-Current Debt (2020)

Nuvalent (NUVL) reported Non-Current Debt of $2.2 million for Q4 2020.

Nuvalent (NUVL) Non-Current Debt (2020) Analysis & Trends

Nuvalent has reported Non-Current Debt for 1 years, with the latest figure at $2.2 million in Q4 2020.

For the quarter ending Q4 2020, Non-Current Debt changed N/A year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2020 stood at $2.2 million (changed N/A YoY), and the FY2020 full-year result was $2.2 million, changed N/A from the prior year.
Non-Current Debt for Q4 2020 stood at $2.2 million.
The five-year high for Non-Current Debt was $2.2 million in Q4 2020, with the low at $2.2 million in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	319.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Nuvalent	9.70 Bn	9.70 Bn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2020	2.24 Mn
Dec 31, 2020	2.24 Mn